tbuckley/cabot-search huggingface dataset:
Markers of human papillomavirus infection and their correlation with cervical dysplasia in human immunodeficiency virus-positive women
Authors: E. Riva, D. Serraino, A. Pierangeli, F. Bambacioni, S. Zaniratti, C. Minosse, M. Selleri, M. Bucci, C. Scagnolari, A.M. Degener, M.R. Capobianchi, G. Antonelli, F. Dianzani
Journal: Clinical Microbiology and Infection (2006)
Effects of Antiretroviral Therapy on Kaposi’s Sarcoma–Associated Herpesvirus (KSHV) Transmission Among HIV-Infected Zambian Children
Authors: Landon N. Olp, Veenu Minhas, Clement Gondwe, Chipepo Kankasa, Janet Wojcicki, Charles Mitchell, John T. West, Charles Wood
Journal: JNCI Journal of the National Cancer Institute (2015)

The risk of Kaposi's sarcoma-associated herpesvirus (KSHV) acquisition among children is increased by HIV infection. Antiretroviral therapy (ART) was recently made widely available to HIV-infected children in Zambia. However, the impact of early ART on KSHV transmission to HIV-infected children is unknown.We enrolled and followed a cohort of 287 HIV-exposed, KSHV-negative children under 12 months of age from Lusaka, Zambia, to identify KSHV seroconversion events. Potential factors associated with KSHV infection-with an emphasis on HIV, ART, and immunological measures-were assessed through structured questionnaires and blood analyses. Incidence rate, Kaplan-Meier, and multivariable Cox regression models were used to assess differences in time to event (KSHV seroconversion) between groups. All statistical tests were two-sided.During follow-up, 151 (52.6%) children underwent KSHV seroconversion. Based on 3552 months of follow-up, we observed similar KSHV incidence rates between HIV-infected and uninfected children. Among HIV-infected children, ART-naïve children had statistically significantly increased risk of KSHV acquisition (adjusted hazard ratio [AHR] = 5.04, 95% confidence interval [CI] = 2.36 to 10.80, P < .001). Time-updated CD4(+) T-cell percentage was also statistically significantly associated with risk of KSHV acquisition (AHR = 0.82, 95% CI = 0.74 to 0.92, P < .001), such that each 5% increase of CD4(+) T-cells represented an 18% decrease in risk of acquiring KSHV.Our data suggest that early ART and prevention of immune suppression reduce the risk of KSHV acquisition among HIV-infected children in an area where both viruses are highly endemic. This study highlights the importance of programs in Africa to provide children with ART immediately after HIV infection is diagnosed.
The Overt Aggression Scale for the objective rating of verbal and physical aggression
Authors: Stuart C. Yudofsky, Jonathan M. Silver, Wynn Jackson, Jean Endicott, Daniel Williams
Journal: American Journal of Psychiatry (1986)

The authors describe the design and reliability of a rating scale that measures aggressive behaviors in adults and children. On the Overt Aggression Scale (OAS), aggression is divided into four categories: verbal aggression, physical aggression against objects, physical aggression against self, and physical aggression against others. In addition, specific interventions related to each aggressive event can be recorded on the OAS. The clinical and research applications of this scale are discussed.
Association of therapy with sunitinib and treatment-related hyperparathyroidism in renal cell carcinoma
Authors: V. Gruenwald, M. Fenner, M. Varvenne, C. Reuter, A. Ganser, P. Ivanyi
Journal: Journal of Clinical Oncology (2009)

e16023 Background: Targeted therapies have been thought to combine high potency with high specifity. With increasing experience with multitargeted tyrosine kinase inhibitors (MTKI) recent findings suggest various interactions with physiological organ functions. Here, we report on abnormalities of the mineral metabolism in patients with renal cell carcinoma (RCC) treated with MTKI. Methods: We identified a total of 61 patients with metastatic RCC and evaluable markers of bone metabolism, which were either treated at our institution (N=53) or followed (N=8) during March 2005 and December 2008. Chemistry and parathyroid hormone (PTH) tests were assessed retrospectively. Patients received either sunitinib (4 weeks on/2 weeks off schedule) or sorafenib (continuous dosing) for metastatic disease. PTH, calcium and phosphate were either determined prior to, during and in some cases after completion of therapy with MTKI. Statistical analyses included either student's t-test or one-way ANOVA. Results: Of 61 evaluable patients, 47 received sunitinib, 6 sorafenib, and 8 patients follow-up only. Mean phosphate levels significantly decreased during treatment from 1.151 (CI 1.077–1.224) to 0.9264 (CI 0.844–1.008) (P&lt;0.0001), whereas mean calcium levels remained unchanged (2.37; CI 2.30–2.44 and 2.36; CI 2.28–2.43 mmol/l, respectively). Treatment with MTKI resulted in increased mean levels of PTH (118.3; CI 91.37–145.2), when compared to baseline 43.52 (CI 30.94–56.10) (P&lt;0.0001). In 4 patients additional values after end of therapy were evaluable, which showed reversible PTH increase (42.7; CI 7.473–77.93). Increase of PTH remained significant for treatment with either sorafenib or sunitinib (P0.05). Conclusions: Treatment with MTKI is associated with dysregulated parathyroid axis, which may have clinical implications in a number of patients and therefore should be monitored throughout the treatment. The mechanism for hormone disturbances remains elusive, but may involve the PDGFR, which plays a major role in transmitting signaling of the bone metabolism. [Table: see text]
Diagnostic value and complications of transthoracic fine needle aspiration in lung lesions
Authors: Cigdem Baskara, Murat Kiyik, Huseyin Cem Tigin, Mehmet Tunc Karadeli, Tulay Sonmez, Aysin Durmaz, Hayati Ozyurt, Sadettin Cikrikcioglu
Journal: European Respiratory Journal (2011)

Objective:  Our aim was to determine the diagnostic value and complications of transthoracic fine needle aspiration (TFNA) -generally used especially in peripheral lung lesions- prospectively.   Material and method:  We performed TFNA under computed tomography with 18- 20 gauge spinal needles to 281 patients in Yedikule Chest Diseases Hospital between 11st March 2009 and 21st July 2010. All patients had chest X rays on 1st and 3rd hours to rule out pneumothorax.   Results:  Mean age of patients was 59±12.5. 49 of patienst were female and 232 males. We obtained COPD in 51 patients of 188 that pulmonary function tests applied. We performed total 367 TFNA in all 281 patients. Any of complications arised in 64 (22.7%) patients; pneumothorax in 37 (13.1%) and hemoptysis in 11 (3.9%). We found COPD is not a significant factor that increases the risk of pneumothorax or any other complications. Also, we didn9t find any differences between 18 and 20 gauge needles in complication rate. We established increased risk of pneumothorax and other complications as the lesion gets larger. We performed chest x ray on 3rd hour in patients with normal chest x ray on 1st hour and pneumothorax wasn9t seen. We obtained results as malign in 182 and benign in 84 patients. We couldn9t obtain any diagnosis in 15 patients. Acid-fast staining of TFNA was positive in 5 of 19 tuberculosis patients. The sensitivity of TFNA was 90.6% in malignancies and 51.9% in pulmonary infections.   Conclusion:  TFNA is a common method with high sensitivity in diagnosing peripheral lung lesions.The most important complications of process are pneumothorax and hemoptysis. Only chest x ray on 1st hour after process is enough to rule out pneumothorax.
Abstract 4522: Elevation of Matrixmetalloproteinases in Different Areas of Thoracic Aortic Aneurysm in Bicuspid And Tricuspid Aortic Valve
Authors: Salah A. Mohamed, Kerstin Schoellermann, Detlev Schult-Badusche, Elisabeth Theissing, Thorsten Hanke, Bjoern E. Wenzel, Frank Noack, Alexander Gosslau, Hans H. Sievers
Journal: Circulation (2009)
Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study.
Authors: W P McGuire, W J Hoskins, M F Brady, H D Homesley, W T Creasman, M L Berman, H Ball, J S Berek, J Woodward
Journal: Journal of Clinical Oncology (1995)

We report a prospective randomized trial in women with advanced ovarian cancer to evaluate the importance of chemotherapy dose-intensity on survival, progression-free survival (PFS), and response.A total of 485 patients with epithelial ovarian cancer and residual masses more than 1 cm following surgery (stage III presentation) or any stage IV presentation were randomly assigned to receive either standard therapy (cyclophosphamide 500 mg/m2 and cisplatin 50 mg/m2 intravenously every 3 weeks for eight courses) or intense therapy (cyclophosphamide 1,000 mg/m2 and cisplatin 100 mg/m2 intravenously every 3 weeks for four courses). Dose modification was rigidly controlled to maintain intensity. Clinical and pathologic responses were assessed, when appropriate, as well as PFS interval and survival.A total of 458 patients met all eligibility criteria and were assessed for survival and PFS. The dose-intensive group received the same total dose of cyclophosphamide and cisplatin, but 1.97 times greater dose-intensity than the standard group. Clinical and pathologic response rates; response duration, and survival were similar in both groups of patients. Hematologic, gastrointestinal, febrile episodes, septic events, and renal toxicities were significantly more common and severe in the dose-intensive group.A doubling of the dose-intensity in the treatment of bulky ovarian epithelial cancers led to no discernible improvement in patient outcome and was associated with more severe toxicity. This study provides no evidence to support the hypothesis that modest increases in dose-intensity without increasing total dose are associated with significant improvement in overall survival or PFS.
Molecular mechanisms underlying gemcitabine resistance in pancreatic cancer and restoration of sensitivity using lenalidomide.
Authors: A. G. Dalgleish, J. B. Bartlett, C. Galustian, R. A. Fryer
Journal: Journal of Clinical Oncology (2010)

e13630 Background: Gemcitabine is the leading therapeutic for the treatment of pancreatic cancer, despite emergence of resistance. Understanding the mechanisms of gemcitabine resistance and discovery of agents that increase tumor cell sensitivity is therefore of clinical importance. Lenalidomide is approved for use in multiple myeloma (MM) in combination with dexamethasone and in del 5q myelodysplastic syndromes (MDS), where immunomodulatory and direct tumoricidal effects may be crucial for clinical activity. However, there is an apparent lack of solid tumor cell sensitivity to this agent. We have investigated the gemcitabine sensitivity of three pancreatic cell lines; PANC-1, MIA-PaCa-2 and BxPC-3 and the effect of lenalidomide addition. Methods: CellTiter-Blue assay was used to detect changes in cell viability. Western blot analysis was used to examine protein expression in untreated and treated cells. Transfection was used to overexpress MEK in gemcitabine-sensitive cells and U0126 was used to inhibit MEK in gemcitabine-resistant cells. Results: We found that PANC-1 cells display greatest resistance to gemcitabine and MIA-PaCa-2 are most sensitive. In addition, PANC-1 exhibits high pERK expression and MIA-PaCa-2 exhibits low expression. Combining gemcitabine and lenalidomide decreased gemcitabine antiproliferation IC50 by up to 40% (p<0.05). Lenalidomide significantly reduced pERK expression in all cells (p<0.05). We tested whether gemcitabine sensitivity could be increased in combination with a pERK-reducing agent and found that the MEK-specific inhibitor U0126 significantly increased cell killing by gemcitabine from 30-60% (p<0.001). We transfected the gemcitabine sensitive MIA-PaCa-2 cells with a constitutively- active MEK mutant and this led to decreased killing by gemcitabine from 54-16% (p<0.05). Conclusions: Constitutively activated MAPK/ERK appears to play an important role in gemcitabine resistance and the addition of a known MEK inhibitor or lenalidomide, which we show to inhibit pERK enhances gemcitabine activity. This indicates that gemcitabine with lenalidomide may be a useful combination to explore in the treatment of pancreatic cancer. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Celgene Celgene Celgene Celgene Celgene
High-throughput amplification fragment length polymorphism (htAFLP) analysis identifies genetic lineage markers but not complement phenotype-specific markers in Moraxella catarrhalis
Authors: J.P. Hays, R. Gorkink, G. Simons, J.K. Peeters, K. Eadie, C.M. Verduin, H. Verbrugh, A. van Belkum
Journal: Clinical Microbiology and Infection (2006)
Local Adoptive Transfer of Antitumor Cellular Immunity to Xenogeneic Animals Studied With a Rapid Radioisotopic Footpad Assay2
Authors: Noritoshi Takeichi, George C. Economou, Charles W. Boone
Journal: JNCI Journal of the National Cancer Institute (1976)

The antitumor cellular immune response to Gross virus-induced rat tumor cells in F344 rats, as measured by a sensitive radioisotopic footpad assay, was adoptively transferred to syngeneic rats and to xenogeneic irradiated BALB/c mice. Xenogeneic transfer was accomplished by the injection of a mixture of rat tumor cells and syngeneic spleen cells, peritoneal exudate cells, or blood lymphocytes from specific immune rats into the footpads of mice. Peritoneal exudate cells produced the strongest footpad reaction in xenogeneic recipients. Use of the xenogeneic adoptive transfer system in a bioassay for human antitumor immunity appeared feasible.
Economic evaluation of sunitinib, sorafenib, bevacizumab/interferon-alfa or temsirolimus in 1st-line treatment of metastatic renal cell carcinoma (mRCC): An indirect comparison
Authors: A. Benedict, C. Charbonneau, J. Hidi, S. T. Kim, S. Négrier
Journal: Journal of Clinical Oncology (2008)

5048 Background: Several new drugs are available as 1st-line therapies in mRCC. Sunitinib malate (SU) showed superior clinical efficacy vs. interferon-α (IFN-α) in a randomized phase III study (Motzer RJ et al. NEJM 2007). Sorafenib (SFN), temsirolimus (TMS) and bevacizumab+IFN-α (BEV/I) have also been compared with IFN-α in phase II/III studies, but no head-to-head trial has assessed SU vs. the new agents. To assist treatment choice in mRCC, we compared the economic value of SU vs. the new drugs from a US third-party payer perspective. Methods: A Markov model with a 10-year time horizon was developed to assess the cost-efficacy of SU vs. SFN, TMS and BEV/I as 1st-line therapy. The model projected survival and costs in 6-week cycles based on extrapolation of survival data with IFN-α, and hazard ratios (HRs) from clinical trials against IFN-α. Endpoints were PFS, overall survival (OS), quality of life, adverse events (AEs), and change in dose intensity. The model incorporated second-line treatment and best supportive care (BSC). Efficacy was measured in life-years (LY), progression-free LY (PFLY), and quality-adjusted LY (QALY) gained. Resource utilization included drugs, tests, scans, monitoring, physician visits, hospitalizations and AE management. Costs and survival benefits were discounted at 3%/year. Costs were applied in 2007USD. Results were expressed as incremental cost per incremental LY, PFLY and QALY. Scenario and probabilistic sensitivity analyses were conducted. Results: Projected PFS and OS were longer with SU than the comparators. Incremental 10-year cost- efficacy ratios of SU vs. SFN were USD57,545/LY, USD28,000/PFLY, and USD60,005/QALY gained. TMS and BEV/I were dominated by SU. Comparing all 4 drugs >USD70,000 willingness to pay for a QALY, SU had the highest probability of the greatest cost-efficacy. Key drivers were HRs, and costs of drugs, 2nd-line therapy and BSC. Conclusions: Based on indirect treatment comparisons, SU is a cost- effective alternative to SFN, TMS and BEV/I as 1st-line therapy in mRCC. Cost-effectiveness ratios were within the established threshold that society is willing to pay for health benefits (USD50,000–100,000/LY or QALY). Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Pfizer Pfizer Pfizer Pfizer
Abstract 293: Comprehensive Genetic Analysis of the Platelet Activating Factor Acetylhydrolase Gene and Cardiovascular Disease in Case/Control and Family Datasets
Authors: Beth S Sutton, David R Crosslin, Svati H Shah, Sarah C Nelson, Anthony C Bassil, A B Hale, Carol Haynes, Pascal J Goldschmidt-Clermont, Jeffery M Vance, William E Kraus, Simon G Gregory, Elizabeth R Hauser
Journal: Circulation (2007)

Platelet Activating Factor Acetylhydrolase (PAFAH) is a potent pro- and anti-inflammatory molecule that has been implicated in multiple inflammatory disease processes, including cardiovascular disease. The goal of this study was to investigate the genetic effects of PAFAH in two large, independent coronary artery disease (CAD) datasets (CATHGEN and GENECARD) to better elucidate its genetic role in CAD. Using a haplotype tagging (ht) approach, 19 htSNPs were genotyped in CATHGEN case/control samples (cases = 807 and controls = 267) and in the GENECARD Family Study (n= 1,101 families, 2,954 individuals). Single SNP analysis using logistic regression was performed on all CATHGEN subjects, resulting in nine SNPs showing significant association in all CATHGEN subjects (P-values ranged 0.0004 – 0.02). CATHGEN cases were further stratified into subgroups based on age of CAD onset (AOO) and severity of disease; 600 young affecteds (YA, AOO&lt;56) and 207 old affected (OA, AOO &gt;56) to provide a consistent validation set for the early onset CAD GENECARD Family study. After stratification of subjects based on AOO, the OA subgroup remained the most associated, with 14 SNPs significantly associated (P-value ranged 0.0001– 0.02). Logistic regression analysis of the GENECARD probands resulted in similar association to that seen in the YA CATHGEN cases (P-values ranged 0.002– 0.05). Of the 19 SNPs genotyped, three SNPs (I198T, A379V, and R92H) were nonsynonymous coding changes. Interestingly, rs1051931 (A379V) and rs1805017 (R92H) constituted the most significantly associated SNPs, even after Bonferroni correction and appear to represent independent associations (r 2 = 0.09). Haplotype analysis was also performed on all 19 SNPs using a two-SNP sliding window approach, resulting in significant association in 161 of 171 haplotypic combinations. In summary, PAFAH represents an important, potentially functional candidate in the pathophysiology of CAD based on numerous associations using two independent data sets and multiple statistical approaches. Functional studies are warranted to evaluate the functional consequences of R92H and A379V polymorphisms.
Efalizumab in the treatment of psoriasis
Authors: Wolf-Henning Boehncke
Journal: Journal of the American Academy of Dermatology (2005)

The humanized antibody efalizumab is currently the only T-cell directed biologic approved for the treatment of moderate-to-severe psoriasis by both American and European authorities. Binding to and blocking the function of the adhesion molecule leukocyte function associated antigen 1 (LFA-1), it is believed to interfere with T-cell activation in the lymph node, migration through the circulation into the skin, and re-activation in-loco, all of these representing central steps in the pathogenesis of psoriasis. A comprehensive clinical development program provided large and consistent evidence that efalizumab induces a major clinical benefit in psoriasis. Efalizumab rapidly and substantially improves psoriatic skin symptoms and leads to profound gain in quality of life. It allows safe and effective long-term control of psoriasis. Therefore, evidence-based treatment guidelines recommend its use in moderate to severe plaque-type psoriasis.
Conservative surgical management of subungual (matrix derived) melanoma: report of seven cases and literature review
Authors: N. Sureda, A. Phan, N. Poulalhon, B. Balme, S. Dalle, L. Thomas
Journal: British Journal of Dermatology (2011)

Journal Article Conservative surgical management of subungual (matrix derived) melanoma: report of seven cases and literature review Get access N. Sureda, N. Sureda Department of Dermatology, Claude Bernard University, Hôpitaux de Lyon, Centre Hopitalier Lyon Sud, 69495 Pierre Bénite Cedex, France Search for other works by this author on: Oxford Academic Google Scholar A. Phan, A. Phan Department of Dermatology, Claude Bernard University, Hôpitaux de Lyon, Centre Hopitalier Lyon Sud, 69495 Pierre Bénite Cedex, France Search for other works by this author on: Oxford Academic Google Scholar N. Poulalhon, N. Poulalhon Department of Dermatology, Claude Bernard University, Hôpitaux de Lyon, Centre Hopitalier Lyon Sud, 69495 Pierre Bénite Cedex, France Search for other works by this author on: Oxford Academic Google Scholar B. Balme, B. Balme Department of Dermatology, Claude Bernard University, Hôpitaux de Lyon, Centre Hopitalier Lyon Sud, 69495 Pierre Bénite Cedex, France Search for other works by this author on: Oxford Academic Google Scholar S. Dalle, S. Dalle Department of Dermatology, Claude Bernard University, Hôpitaux de Lyon, Centre Hopitalier Lyon Sud, 69495 Pierre Bénite Cedex, France Search for other works by this author on: Oxford Academic Google Scholar L. Thomas L. Thomas Department of Dermatology, Claude Bernard University, Hôpitaux de Lyon, Centre Hopitalier Lyon Sud, 69495 Pierre Bénite Cedex, France Luc Thomas. E‐mail: luc.thomas@chu‐lyon.fr Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 165, Issue 4, 1 October 2011, Pages 852–858, https://doi.org/10.1111/j.1365-2133.2011.10477.x Published: 01 October 2011
Unusual depression and Tc-99m ethyl cysteinate dimer SPECT brain uptake.
Authors: THIERRY VANDER BORGHT, BEATRICE DE COENE, SANDRINE CHARLET, CLAUDE GILLIARD, CHRISTINE REYNAERT
Journal: Clinical Nuclear Medicine (2001)

VANDER BORGHT, THIERRY M.D., Ph.D.; DE COENE, BÉATRICE M.D.; CHARLET, SANDRINE B.Sc.; GILLIARD, CLAUDE M.D.; REYNAERT, CHRISTINE M.D., Ph.D. Author Information
Migration and Psychopathology of Eskimo Women
Authors: JOSEPH D. BLOOM
Journal: American Journal of Psychiatry (1973)

Various epidemiological studies have noted the high rate of migration of Eskimo women from their native villages into cities and large rural towns and also their higher rate of psychopathology compared to Eskimo men. The author explores both trends and correlates them, theorizing that the Eskimo woman's dissatisfaction with her low standing in the native culture provides impetus for migration in the hope of marrying a nonnative man. This uprooting, along with unsatisfactory integration into the new culture, may lead to increased psychopathology.